Agenus to Present at the 17th Annual BIO CEO & Investor Conference
Published on Agenus Bio Investor Center (http://investor.agenusbio.com/) on 2/3/15 11:30 am EST
Agenus to Present at the 17th Annual BIO CEO & Investor Conference
Release Date:
Tuesday, February 3, 2015 11:30 am EST
Terms:
Dateline City:
LEXINGTON, Mass.
LEXINGTON, Mass.--( BUSINESS WIRE [1])--Agenus Inc. (NASDAQ: AGEN), an immunology company developing a series of immune-oncology checkpoint modulators (CPMs), heat shock protein peptide-based vaccines, and immune adjuvants, today announced that the Company will present at the 17th Annual BIO CEO & Investor Conference on Monday, February 9th at 4:30 p.m. Eastern Time. The conference will take place at the Waldorf Astoria Hotel in New York City.
Webcast Information
The live and archived webcast of the presentation will be accessible from the Company’s website at www.agenusbio.com/webcast [2]. Please log in approximately 5-10 minutes before each event to ensure a timely connection. The archived replay will be available on the Agenus website for one month following the conference.
About Agenus
Agenus is an immunology company developing a series of immuno-oncology CPMs, heat shock protein peptide-based vaccines and immune adjuvants. These programs are supported by three separate technology platforms. Agenus’ checkpoint modulator programs target GITR, OX40, CTLA-4, LAG-3, TIM-3 and PD-1. The company’s proprietary discovery engine Retrocyte DisplayTM is used to generate fully human and humanized therapeutic antibody drug candidates. The Retrocyte Display platform uses a high-throughput approach incorporating IgG format human antibody libraries expressed in mammalian B-lineage cells. Agenus’ heat shock protein vaccines have completed Phase 2 studies in newly diagnosed glioblastoma multiforme, and in the treatment of herpes simplex viral infection; the heat shock protein platform can generate personalized as well as off the shelf products. The company’s QS-21 Stimulon® adjuvant platform is extensively partnered with GlaxoSmithKline and Janssen Sciences Ireland UC and includes several candidates in Phase 2, as well as shingles and malaria vaccines which have successfully completed Phase 3 clinical trials. For more information, please visit www.agenusbio.com [3], or connect with the company on Facebook, LinkedIn, Twitter and Google+.
Forward-Looking Statement
This press release contains forward-looking statements, including statements regarding the Company’s upcoming corporate presentation. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission for the period ended September 30, 2014. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Language:
English
Contact:
Media:
BMC Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com [4]
or
Investors:
Argot Partners
Andrea Rabney/Jamie Maarten, 212-600-1902
andrea@argotpartners.com [5]
jamie@argotpartners.com [6]
Ticker Slug:
Ticker:
AGEN
Exchange:
NASDAQ |
